Status:
COMPLETED
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in SLE with poten...
Detailed Description
Systemic lupus erythematosus (SLE) is a rare and potentially life-threatening auto-immune systemic disease. There is an urgent need for better comprehension of the physiopathology of the disease and t...
Eligibility Criteria
Inclusion
- Adult patient aged over 18 years old
- Diagnosis of systemic lupus erythematosus
- Affiliated person or beneficiary of a social security scheme.
- Having signed an informed consent (at the latest on the day of inclusion and before any examination required by research).
Exclusion
- Pregnant or breastfeeding women,
- Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Key Trial Info
Start Date :
October 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04440566
Start Date
October 13 2020
End Date
February 14 2022
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Service d'Immunologie et Immunogénétique
Bordeaux, France